Retatrutide vs Tirzepatide

The numbers, side by side

Retatrutide and tirzepatide both work on overlapping hormone receptors and are both dosed once weekly, but the table below is not a head-to-head trial result: no published study has enrolled participants to both drugs and compared them directly. Each row pulls from that drug’s own separate evidence base, labeled as such where it matters most.

Treat the weight-loss row with particular care. Retatrutide’s 24.2% and 22.8% figures come from a double-blind, placebo-controlled phase 2 trial of 338 adults, published by Jastreboff, Kaplan, Frías and colleagues in the New England Journal of Medicine in 2023 (DOI: 10.1056/NEJMoa2301972). Tirzepatide’s 20.2% figure comes from a separate trial entirely, SURMOUNT-5, an open-label, active-comparator trial of 751 adults run by Aronne, Horn, le Roux, Ho and colleagues, published in the New England Journal of Medicine in 2025 (DOI: 10.1056/NEJMoa2416394). Different design, more than twice the enrollment, and 24 additional weeks of follow-up separate the two results, so lining up 24.2% against 20.2% and calling the gap a head-to-head margin is exactly the mistake this page is trying not to make. Both numbers are real; neither was measured against the other.

The mechanism row is worth sitting with too, because it explains why people search “retatrutide vs tirzepatide” in the first place. Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide activates those same two receptors and adds a third, glucagon. That third pathway is the structural reason retatrutide is described as a triple agonist rather than a dual agonist, and it is the leading mechanistic explanation researchers point to for retatrutide’s larger trial result. More receptor pathways is not automatically better for every patient, but it is the actual difference in how the two molecules are built, as opposed to a marketing distinction.

Why retatrutide’s bigger number doesn’t make it the better choice

Retatrutide’s 24.2% weight-loss figure is real, but it describes a trial result, not a treatment you can start, and not a proven margin over tirzepatide’s own 20.2% figure either, since the two numbers were never measured in the same trial. A larger number in a phase 2 study is a promising research finding. It is not the same thing as an approved medication sitting on a pharmacy shelf, and for anyone deciding what to actually do about their weight this year, that difference matters more than the extra percentage points.

Retatrutide has no FDA-approved dosing label, which means there is no official starting dose, titration schedule or missed-dose guidance for a clinician to prescribe from, only the protocol used inside its own clinical trial. It has no pharmacy supply chain, so even a clinician who wanted to prescribe it has nothing to write a prescription for. And it has no clinician supervision available outside a trial setting, which means none of the monitoring, dose adjustment or side-effect management that comes standard with an approved medication. Tirzepatide clears all three of those bars today. That is the entire basis for the “decisive advantage” framing at the top of this page: it is not a claim that tirzepatide outperforms retatrutide, it is a statement about which one exists as a real, prescribable option right now.

It helps to separate two different questions that “which is better” usually blurs together. One question is scientific: which molecule produced more weight loss in the trial that measured it. On that narrow question, retatrutide’s phase 2 result is the larger number. The other question is practical: which drug can a person actually start this month, with a clinician who can adjust the dose, monitor for side effects and answer questions along the way. On that question, only tirzepatide has an answer at all, because retatrutide’s answer is currently “not outside a trial.” Most people typing “retatrutide vs tirzepatide” into a search bar are really asking the second question, even when the framing sounds like the first.

The gap between those two questions is also why “wait for retatrutide” is not free advice. Retatrutide is currently in phase 3 trials, and no approval date has been published, so there is no way to know whether that wait is measured in months or years. Tirzepatide’s approval, by contrast, is a settled fact, not a projection.

What the phase 2 trial actually found

Retatrutide’s headline weight-loss numbers come from one published source: a double-blind, randomized, placebo-controlled phase 2 trial that enrolled 338 adults, registered as ClinicalTrials.gov NCT04881760 and led by Ania M. Jastreboff of Yale, with co-authors including Lee M. Kaplan of Harvard and Juan P. Frías. The results were published as “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial” in the New England Journal of Medicine, 2023;389(6):514-526 (DOI: 10.1056/NEJMoa2301972, PMID 37366315). This comparison uses the trial’s two highest dose arms, 8 mg and 12 mg, alongside placebo, since those are the figures given at the top of this page.

These are least-squares means, a statistical adjustment for small baseline differences between trial arms, the standard reporting method for a randomized trial and the figure the journal itself published. The gap between the active doses and placebo is large: even the 8 mg arm produced more than ten times the weight loss reported on placebo at 48 weeks. That gap is what makes retatrutide’s trial result newsworthy. It is also, on its own, silent on the question of access: a trial result describes what happened inside a controlled study, not what a clinician can prescribe outside one, which is the distinction the rest of this page is built around.

The double-blind, placebo-controlled design is what makes that gap trustworthy in the first place, rather than a coincidence of who enrolled in which arm. Neither participants nor the researchers assessing their weight change knew who was on retatrutide and who was on a matching placebo injection, which is what keeps expectation, on either side, from quietly inflating the reported result. Randomizing 338 adults across dose arms and placebo is also what lets the trial attribute the weight-loss difference to the drug itself rather than to differences between the people who happened to land in each group. That rigor is exactly why this page treats the 24.2% and 22.8% figures as solid evidence of what retatrutide did inside the trial, while still being careful never to extend that same evidence to a claim about tirzepatide, which the trial did not test.

Tirzepatide: what you can get today

Tirzepatide is the one of these two drugs a licensed clinician can actually prescribe today. It is FDA-approved and dosed once weekly by subcutaneous injection, the same route retatrutide uses in its trial, but with a real prescribing label behind it. It is marketed under two brand names for two approved uses: Mounjaro for type 2 diabetes and Zepbound for weight loss.

Tirzepatide’s own trial evidence is concrete too. In SURMOUNT-5, a phase 3b, open-label, active-comparator trial of 751 adults with obesity led by Aronne, Horn, le Roux, Ho and colleagues, tirzepatide at the maximum tolerated dose (10 or 15 mg) produced 20.2% mean weight loss at 72 weeks (95% CI −21.4 to −19.1), published in the New England Journal of Medicine in 2025 (DOI: 10.1056/NEJMoa2416394, PMID 40353578, NCT05822830). That trial compared tirzepatide against semaglutide, not against retatrutide, and it was open-label, meaning participants and investigators both knew which drug each person was taking, and funded by Eli Lilly, the company that manufactures tirzepatide. Neither fact makes the 20.2% figure false, but both are reasons to read it carefully rather than as a blinded, independently funded result, and neither turns SURMOUNT-5 into a comparison against retatrutide, which the trial never enrolled.

Being prescribable is not a minor footnote next to retatrutide’s trial result, it is the entire practical difference between the two drugs. Tirzepatide comes with an approved dosing schedule, a licensed clinician to evaluate whether it is appropriate for a given person, and ongoing supervision to manage side effects as the dose is raised, none of which retatrutide can currently offer outside a clinical trial. A clinician who prescribes tirzepatide is working from a real label; a clinician asked about retatrutide has nothing to prescribe from at all.

The providers above evaluate eligibility and prescribe tirzepatide or semaglutide, the two GLP-1-class medications currently available by prescription. Neither offers retatrutide, because no licensed provider can: it remains investigational, still moving through the clinical-trial process that produced the numbers earlier on this page.

Starting tirzepatide follows the same shape of process the retatrutide trial itself relied on for its 338 participants: an initial evaluation, a low starting dose, and a schedule that steps the dose up gradually while a clinician checks in on how it is tolerated. The difference is that tirzepatide’s version of that process is available to the public through an approved label, while retatrutide’s version currently exists only inside the trial infrastructure that is still generating its evidence base. For someone comparing the two drugs because they want to act now rather than watch a trial from the sidelines, that is the whole answer.

Who each one is for

Tirzepatide is for people who want to start a GLP-1-class treatment now, under a licensed clinician’s supervision. If a doctor evaluates someone as an appropriate candidate, either for type 2 diabetes (Mounjaro) or for weight management (Zepbound), tirzepatide is an approved, prescribable option today. That is a real, near-term decision, not a hypothetical one.

Retatrutide is not, at this point, “for” any specific patient, because no patient outside a clinical trial can currently be prescribed it. Its phase 2 result is a reason to watch its later-stage trials with interest, not a reason to search for a way around the fact that it has no approved label, no pharmacy supply and no supervised path to treatment outside the trial infrastructure that is still testing it. Anyone drawn to retatrutide specifically by its 24.2% figure is, realistically, a person interested in where the drug class is headed, not someone with a treatment option in front of them today.

Neither drug is appropriate for self-directed use. A licensed clinician’s evaluation, of individual health history, other medications and whether a GLP-1-class medication is appropriate at all, is the step that has to happen before starting tirzepatide, exactly as it happened for every participant in retatrutide’s own trial. That evaluation is not an optional formality; it is the mechanism by which either drug is used safely, and it is unavailable to anyone trying to obtain retatrutide outside the trial setting where that supervision exists.

Sources

Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial.” New England Journal of Medicine, 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972. PMID 37366315. Registered as ClinicalTrials.gov NCT04881760. This is the primary source for every retatrutide figure on this page.

Aronne LJ, Horn DB, le Roux CW, Ho W, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” New England Journal of Medicine, 3 July 2025. DOI: 10.1056/NEJMoa2416394. PMID 40353578. Registered as ClinicalTrials.gov NCT05822830 (SURMOUNT-5). This is the primary source for tirzepatide’s 20.2% weight-loss figure on this page. The trial was open-label and funded by Eli Lilly, which manufactures tirzepatide.

Rosenstock J, Frías J, et al. reported retatrutide’s effect in people with type 2 diabetes in a separate trial published in The Lancet in 2023. DOI: 10.1016/S0140-6736(23)01053-X.

Bajaj HS, et al. published newer retatrutide trial data in The Lancet on 13 June 2026. DOI: 10.1016/S0140-6736(26)00967-0, more recent than the sources most pages on this topic currently cite.